ongevity covers therapeutics, robotics, and fintech. Yet as an emerging industry how do these get financed when they are so risky? How should venture firms evaluate longevity companies and how should founders attract investors and employees? This symposium will look at these questions specifically as applied to longevity, uniquely from the investor, scientist, and the founder viewpoint. The symposium will provide a foundation to the field with talks from investors, scientists and company founders who will explain their respective perspectives, and will include talks from Stanford faculty involved with startups and spinouts.
Register here: Stanford Applied Longevity Translation Symposium | Department of Genetics | Stanford Medicine
9am: Conference Welcome
Anastasiya Giarletta, Principal, Longevity Investments, R42 Group; Instructing Team, Stanford courses: Longevity Science and Technology; Longevity Venture Capital
9:05am: Aging Science and Technology
● Ronjon Nag, PhD, Adjunct Professor in Genetics, Stanford; Instructor, Stanford courses: Longevity Science and Technology; Longevity Venture Capital
-Overview of aging;
-Translational and investment challenges
9.35am: Monitoring Health and Aging Using Deep Data
● Michael Snyder, Professor Stanford University, Chair, Dept. of Genetics; Director, Center for Genomics and Personalized Medicine
- Deep data are powerful for health monitoring
- People age differently
- Health can be monitoring remotely using wearables and microsampling
10:05am: Can young blood reverse aging?
● Tony Wyss-Coray, D.H. Chen Distinguished Professor of Neurology and Neurological Sciences and the Director of the Phil and Penny Knight Initiative for Brain Resilience at Stanford University
- Factors in blood target pathways linked to aging
- The brain is a potential target for blood derived factors
10:35am: Break
11:05am: Female Brain Aging
● Dena Dubal, Associate Professor, Neurology, UCSF Weill Institute for Neurosciences
11:40pm: Panel: Brain Aging
● Moderator: Artem Trotsyuk, PhD, HAI Fellow, Instructor Longevity Science
● Dena Dubal, Tony Wyss-Coray
12.10-1 Break & lunch
● We will provide a catered selection of lunch options
1pm: Longevity Therapeutics: killing bad cells of aging and rejuvenating the good ones
● Dr. Marco Quarta, Founder of Rubedo Life Sciences and Turn.bio
1:35pm: Project Blueprint: Next evolution of human
● Bryan Johnson interview by Prof. Michael Snyder
2:10pm: Inflammaging Connects Chronic Disease and Immune Decline in Time and Space
- Dr. David Furman, Director, Stanford 1,000 Immunomes Project; Head, Buck Institute Bioinformatics Core; Associate Professor, Buck Institute for Research on Aging; Founder, Edifice Health Inc, and Cosmica Inc.
- The Immune system and systemic inflammation determine rates of aging in different organs
- Using humans in space and ground analogs as a model for accelerated aging enables rapid identification of geroprotectors
2:45pm: Finding financing for longevity ventures, deal terms for investment and M&A
● Arman Pahlavan, Perkins Coie
● What do venture firms look for
● Deal terms for biotechs
● Biodollar deals
● Grant sources and applying for grants
3:20pm: Mitochondria applications in aging
● Vinit Mahajan, Professor of Ophthalmology, Advisor Mitrix.bio
4pm: Student Lightning Presentations and Longevity Company Competition
5pm: End of Symposium